WO2007069983A1 - Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood - Google Patents
Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood Download PDFInfo
- Publication number
- WO2007069983A1 WO2007069983A1 PCT/SE2006/001421 SE2006001421W WO2007069983A1 WO 2007069983 A1 WO2007069983 A1 WO 2007069983A1 SE 2006001421 W SE2006001421 W SE 2006001421W WO 2007069983 A1 WO2007069983 A1 WO 2007069983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory
- group
- carbohydrate
- pathogenic microbe
- solid substrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/206—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from 5 mammalian blood; use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe,
- glycoconjugates i.e. glycolipids, glycoproteins and proteoglycans, as receptor molecules for cell attachment to facilitate tissue colonization and invasion processes.
- adhesins of the surface of bacteria, viruses, fungi and parasites interact with carbohydrate chains of glycoconjugates which enable microbes to colonize mucosal surfaces and tissue lesions.
- the role of sialic acid in binding of pathogens to host cells has been reported over many years. Only recently proteoglycans with their carbohydrate chains (glycosaminoglycans) were shown to bind many different pathogens .
- cytokines include tumor necrosis factor alpha and beta (TNF- ⁇ and TNF- ⁇ ) , interleukin-1 (IL-I), and interleukin-6 (IL-6) . These cytokines are part of the inflammatory response of sepsis. Multiple organ failure induced by sepsis is currently the leading cause of death in intensive care units.
- cytokines mentioned above have a capacity to bind selectively to a range of glycosaminoglycans, or GAGs, including heparan sulfate in tissues and on the surface of both endothelial cells and leucocytes.
- GAGs glycosaminoglycans
- Heparan sulfate is a glycosaminoglycan that is present on the surface of almost all mammalian cells. It is built up by alternating D-glucosamine and uronic acid residues (L-iduronic and D-glucuronic) . Heparan sulfates are highly charged (sulfated) heterogeneous polysaccharides and represent the carbohydrate portion of many glycoconjugates (syndecan, perlecan, glypican) on the cell surface.
- microbes utilize heparan sulfates on the surface of the mammalian cell as receptors. This mechanism is general and valid for almost all bacteria, virus and parasites. Some microorganisms utilize more than one glycoconjugate receptor. Examples of other receptors that are used together with heparan sulfate are specific chondroitin sulfates and sialic acid containing glycoproteins .
- Heparan sulfate/chondroitin sulfate binding microbes are exemplified by viruses like herpes simplex virus type 1 (HSV-I) , causative agent of orolabial herpes; herpes simplex virus type 2 (HSV-2) , causative agent of genital herpes; cytomegalovirus (CMV) , the major complicating agent in immunosuppressed patients; dengue virus, which causes recurrent fevers; and human immunodeficiency virus (HIV) ; and by bacteria like Helicobacter pylori, Streptococcus sanguis, Streptococcus mutans, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Mycobacterium tuberculosis; and parasites like Plasmodium falciparum (which causes malaria) , and Trypanosoma cruzi (which causes trypanosomiasis)
- cytokines like TNF- ⁇ , also utilize heparan sulfate on cell surfaces for binding and activation. Heparin as a receptor
- Heparin is a polysaccharide, which is isolated from mammalian tissue. Since its discovery in 1916 by the American scientist McLean, heparin has been recognized for its blood anticoagulant properties and heparin has, for more than 50 years, been used clinically as a blood anticoagulant and antithrombotic agent.
- heparin has a very particular distribution in mammalian tissue. Heparin is, in contrast to the heparan sulfates, present only in the basophilic granules of mast cells. However, today, in addition to its established place in prevention and therapy of thromboembolic disorders, heparin has demonstrated a broad spectrum of different activities independent of anticoagulation.
- a large number of proteins in blood bind, with high affinity, to heparin and/or heparan sulfate.
- examples are antithrombin (AT) , fibronectin, vitronectin, growth factors (e.g. the fibroblast growth factors, the insulin like growth factors etc) .
- Human serum albumin (HSA) also binds, but with a lower affinity. On the other hand, HSA is present in large amounts in blood.
- US 6,197,568 dicloses methods for isolation and detection of flaviviruses and other hemorrhagic fever viruses, such as dengue virus, based on the sulfated polyanion-dependent interaction of flaviviruses and hemorrhagic fever viruses .
- Extracorporeal devices are used in a variety of clinical situations including kidney dialysis, cardiopulmonary bypass and plasmapheresis.
- Extracorporeal therapies means procedures in which desired products like oxygen, blood-anticoagulants, anesthetics etc can be added to body fluids . Conversely, undesired products like toxins etc can be removed from body fluids outside the body. Examples are haemodialysis and haemofiltration which represent technologies whereby blood is rinsed from waste products.
- An object of the present invention is to provide a method for treatment of a mammal suffering from diseases or conditions caused or aggravated by different pathogenic microbes, inflammatory cells or inflammatory proteins by removal of said pathogenic microbes, inflammatory cells or inflammatory proteins from the blood of said mammal.
- Another object of the present invention is to provide a method for extracorporeal removal of pathogenic microbes, inflammatory cells or inflammatory proteins from mammalian blood.
- a first aspect of the present invention provides a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood, comprising the steps:
- the prior-art concept of introducing heparin fragments and/or sialic containing fragments into the vascular system of patients has shown limited success, in most cases due to bleeding complications when large amounts of heparin are introduced into the vascular system.
- the method according to the invention circumvents these problems by the carbohydrates being immobilized on a solid surface, as is inter alia described in Preparatory example 6.
- Use of immobilized carbohydrates as defined by the method according to the invention also provides a further unexpected advantage. The inventors have found that the carbohydrate has to be immobilized onto a solid surface to have the capacity that is necessary for binding a significant amount of the compounds that are to be removed.
- Comparative example 1 and Example 1 for HSV-I show that in solution, less than 3 % of the virus binds to an excess of heparin (Comparative example 1) while more than 94 % of the virus binds to immobilized heparin (Example D •
- the method of the present invention enables safe and efficient treatment of patients suffering from sepsis or septic shock by removing pathogens causative of the condition from the patient's blood stream.
- the method of the present invention allows removal of many different pathogenic microbes, inflammatory cells and inflammatory proteins. Examples of pathogenic microbes commonly associated with sepsis that may be removed using the method of the invention include staphylococci, such as Staphylococcus aureus, streptococci and E. coli.
- heparin and heparan sulfates bind to a large number of components, as exemplified in the background section, it was expected that a heparin surface would be covered with many of these proteins, when brought into contact with blood, thus preventing the microbes from attaching.
- the present inventors have surprisingly found that highly efficient purification of serum and whole blood from mammals, including humans, can be achieved using a method and a device according to the present invention. It is disclosed herein that a column of moderate size managed to almost completely remove considerable amounts of viruses from blood serum and whole blood. See e.g. Examples 2, 3 and 4.
- said pathogenic microbe is selected from the group consisting of bacteria, viruses and parasites .
- said pathogenic microbe is a virus.
- said virus is selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, Influenza A virus, cytomegalovirus and human immunodeficiency virus.
- said virus is selected from the group consisting of herpes simplex virus type 1 or herpes simplex virus type 2.
- said pathogenic microbe is a bacterium.
- said bacterium is selected from the group consisting of Helicobacter pylori, Streptococcus sanguis, Streptococcus mutans, Staphylococcus aureus, Escherichia coli, Pseudomonas aureginosa and Mycobacterium tuberculosis.
- said pathogenic microbe is Helicobacter pylori or Staphylococcus aureus.
- said pathogenic microbe is a parasite.
- said parasite is selected from the group consisting of Plasmodium falciparum and Trypanosoma cruzi.
- said inflammatory cell is selected from the group consisting of inflammatory lymphocytes and inflammatory macrophages.
- said inflammatory protein is a pro-inflammatory cytokine.
- said pro-inflammatory cytokine is selected from the group consisting of tumor necrosis factor alpha (TNF- ⁇ ) , tumor necrosis factor beta (TNF- ⁇ ) , interleukin-1 (IL-I) , and interleukin-6 (IL-6) .
- said mammalian blood is human blood.
- said carbohydrate is selected from the group consisting of heparin, heparan sulfate, chondroitin sulfate, carbohydrates comprising sialic acid and carbohydrates comprising neuramic acid.
- said carbohydrate is heparin.
- said solid substrate comprises microparticles or hollow fibres.
- the material of said solid substrate is selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes .
- said carbohydrate is covalently linked to said solid substrate.
- said carbohydrate is linked to said solid substrate by covalent end-point attachment.
- Covalent attachment of a carbohydrate to a solid substrate provides better control of parameters such as surface density and orientation of the immobilized molecules as compared to non-covalent attachment. These parameters have been shown by the inventors to be important in order to provide optimal pathogen binding to the immobilized carbohydrate molecules.
- the surface concentration of the carbohydrate on the solid substrate should preferably be in the range of 1-10 ⁇ g/cm 2 .
- Covalent end-point attachment means that the carbohydrate is covalently attached to the solid substrate via the terminal residue of the carbohydrate molecule.
- a second aspect of the present invention provides use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of a pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood.
- Embodiments of a use according to the second aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization.
- a third aspect of the invention provides use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by a pathogenic microbe, inflammatory cell or inflammatory protein.
- Embodiments of a use according to the third aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization.
- a device as referred to in the use and method according to the invention may comprise a conventional device for extracorporeal treatment of blood and serum from patients, e.g. suffering from renal failure.
- Stable coating no leakage of carbohydrate to the blood in contact therewith.
- a non-limiting example of such a device which can be used in a use or a method according to the present invention, is a pediatric haemoflow dialyzer such as the Prisma MlO haemofilter/dialyzer from Gambro AB, Sweden.
- Other models or types of devices for extracorporeal treatment of blood or serum may also be used.
- a fourth aspect of the present invention provides a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein, comprising the steps:
- a) extracting blood from the subject b) bringing the extracted blood into contact with a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, under conditions allowing binding of a pathogenic microbe, an inflammatory cell or an inflammatory protein to the carbohydrate, and c) reintroducing the blood, containing a reduced amount of said pathogenic microbe, inflammatory cell or inflammatory protein, into the bloodstream of the subject.
- the extraction and reintroduction of blood is performed in a continuous loop, which loop comprises a part of the bloodstream of the subject.
- Embodiments of a method for treatment according to the fourth aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization .
- pathogenic microbe means a microbe, which can cause disease in a living organism when introduced into said organism.
- pathogenic microbes include bacteria, viruses and parasites .
- the term "inflammatory cell” means a cell, which is involved in inflammatory response in a mammal. Examples of “inflammatory cells” include inflammatory lymphocytes and inflammatory macrophages.
- inflammatory protein means a protein, such as a cytokine, released for instance in connection with microbial infection or immunization.
- cytokine means a protein, released for instance in connection with microbial infection or immunization, selected from the group consisting of interleukins, interferons, chemokines and tumour necrosis factors.
- the gel was stabilized by addition of an aqueous solution of NaBHaCN, sodium cyanoborohydride (0.5 g in 100 ml, phosphate buffer, 0.1 M, pH 7.0). The gel was filtered and washed as described above and finally washed with acetate buffer (500 ml, 0.1 M, pH 4.0), yielding aminated Sephadex G 25 (85 g) .
- Aminated Sephadex G 25 (85 g) obtained as described in Preparatory example 1 was suspended in acetate buffer (800 ml, 0.1 M, pH 4.0) and 4.O g nitrous acid degraded heparin (heparin from Pharmacia, Sweden) was added. After shaking for 0.5 h, NaBH 3 CN (0.4 g) was added. The reaction mixture was shaken for 24 h and then processed as above, yielding heparinized Sephadex G 25 (80 g) .
- the gel contains 2 % heparin (w/w, sulfur analysis) .
- the Sephadex G 25 beads have an average diameter of 50- 150 ⁇ m. A rough calculation reveals that 1 cm 3 contains 10 5 beads which gives a bead surface area of 0.03 m 2 /cm 3 . Further, if heparin is attached only to the surface of the beads, a heparinized Sephadex G 25 with 2 % heparin w/w has about 0.003 ⁇ g heparin/cm 2 .
- a glass wool material is heparinized using the general procedure described below.
- Reactive amino functions are introduced on the glass wool surface by treatment with an aqueous solution of polyamine, polyethylenimine (PEI) or chitosan.
- the polyamines may be stabilized on the surface by crosslinking with bifunctional reagents, such as crotonaldehyde or glutaraldehyde .
- the coating is further stabilized by ionic cross linking with a sulfated polysaccharide (dextran sulfate or heparin) . If necessary, these steps are repeated and a sandwich structure is built up. Careful rinsing (water, suitable buffers) should be performed between each step.
- end-point attachment to the aminated surface of native heparin is done by reductive amination, utilizing the aldehyde function in the reducing terminal residue in native heparin.
- the coupling is performed in aqueous solution, by reductive amination (cyanoborohydride,
- a polymeric surface was heparinized using the general procedure described below.
- a oxidizing agent potassium permanganate, ammoniumperoxidisulfate
- the surface can also be etched with plasma or corona.
- Reactive amino functions are introduced by treatment with a polyamine, polyethylenimine (PEI) or chitosan.
- a polyamine polyethylenimine (PEI) or chitosan.
- PEI polyethylenimine
- the polyamines may be stabilized on the surface by cross linking with bifunctional reagents, such as crotonaldehyde or glutaraldehyde .
- the coating is further stabilized by ionic cross linking with a sulfated polysaccharide (dextran sulfate or heparin) . If necessary these steps are repeated and a sandwich structure is built up. Careful rinsing (water, suitable buffers) should be performed between each step.
- end-point attachment (EPA) to the aminated surface of native heparin is done by reductive amination, utilizing the aldehyde function in the reducing terminal residue in native heparin. A more reactive aldehyde function in the reducing terminal residue can be achieved by partial, nitrous degradation of heparin.
- 1-10 ⁇ g/cm 2 of heparin can be coupled to all hydrophilic surfaces like glass, cellulose, chitin etc, and more or less all hydrophobic polymers like polyvinyl chloride, polyethylene, polycarbonate, polystyrene, PTFE etc.
- heparin onto the inner lumen of hollow fibers In this preparatory example, a pediatric haemoflow dialyzer was used.
- the fibers of the dialyzer were made of polysulfone with an inner diameter of 200 microns and a wall thickness of 40 microns.
- the total surface area of the blood contacting material was 4000 cm 2 and the priming volume was 28 ml.
- the aldehyde group at the reducing terminal residue was used for coupling.
- Amination of the fibers was performed as described in Preparatory example 6 and coupling of the oligosaccharide of formula I, which contains terminal sialic acid residues, was performed by circulating the compound of formula I, dissolved in acetate buffer (800 ml, 0.1 M, pH 4.0) together with NaBH 3 CN (0.4 g) , at room temperature for 24 h.
- a solution (10 ⁇ l) containing 10 7 plaque forming units of virus (Herpes simplex virus type 1 strain KOS321) was incubated with 20 ⁇ l of 3 H-labelled heparan sulfate (HS) in a total volume of 400 ⁇ l of buffered NaCl for 30 min at 37 0 C. Thereafter, the solution was centrifuged through a Microsep 1 M filter, retaining virus and bound HS. 2.3 % of HS was bound (479 CPM) to the virus, while 97.7 % of the HS was unbound and passed through the filter.
- HS heparan sulfate
- Preparatory example 2 were soaked in buffered NaCl (PBS) and 0.8 ml was transferred to each of two small disposable columns, forming a gel layer of approximately 1 cm. After washing three times, 50 ⁇ l of 3 H-thymidine radiolabelled viruses were suspended in 150 ⁇ l of PBS. 10 9 plaque forming units of HSV-I, corresponding to 10 11 virus particles, were added to column 1, and 10 8 plaque forming units of HSV-2, corresponding to 10 10 virus particles, were added to column 2. Virus was allowed to adsorb to the respective columns. Thereafter, 0.8 ml of PBS was added to each column and the pass-through fluid was collected for estimation of unabsorbed virus.
- PBS buffered NaCl
- both columns were washed 4 times with 1 ml of PBS, and the washings were collected as fractions for quantification of washed out virus. These, and the following fractions, were transferred to scintillation vials and quantified with regard to amount of virus through determination of cpm in a beta counter.
- the columns were subjected to elution of the respective heparin-bound viruses three times by 1 ml of 2 M NaCl, and the three fractions were collected from each column. Following that, elution was performed by twice adding 1 ml of 5 % SDS in PBS (PBS-SDS) , and the two fractions from each column were collected. Finally, the heparin-coated beads from the two columns were each suspended in 1 ml of PBS-SDS, and 200 ⁇ l aliquots were subjected to quantification of remaining bound virus particles by determination of radioactivity.
- Example 2 The experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-I virus particles at a quantity of 10 9 PFU equivalent to 10 u virus particles were mixed with 0.5 ml of human serum and then applied on heparin-coated beads in a disposable column. Thereafter, the procedure including elution and washing was followed as in Example 1. The results are shown in Table 2 below.
- Example 2 Removal of HSV-I virus particles from human serum by- binding to heparin immobilized on a hollow fiber haemoflow dialyzer
- the experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-I virus particles at a quantity of 10 9 PFU equivalent to 10 11 virus particles were mixed with 0.5 ml of human serum and then applied on the heparin-coated hollow fiber dialyzer of Preparatory example 6. Thereafter, the procedure including elution and washing was followed as in Example 1. The results are shown in Table 3 below.
- Example 1 Removal of HSV-I and HSV-2 virus particles from human whole blood by binding to heparin immobilized on Sephadex beads
- the experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-I and HSV-2 virus particles at a quantity of equivalent to 10 11 virus particles per ml were mixed with 1 ml of human blood and then applied to 1 ml heparin- coated beads in a disposable column. Thereafter, the procedure including elution and washing was followed as in Example 1.
- Virus stocks of Influenza A HlNl were replicated in MDCK cells grown at 35 0 C under standard conditions for 3 days, after which the cells were homogenized and titrated to assess the number of focus-forming units (FFU) /ml.
- Virus particles were suspended in human serum to a final concentration of 10 6 FFU/ml.
- a 10 ml suspension was applied on a sialic acid-coated hollow fiber dialyzer, prepared using the method described in Preparatory example 7.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06835845.6A EP1960016B1 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
MX2008007716A MX2008007716A (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood. |
AU2006325531A AU2006325531B2 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
BRPI0619820-1A BRPI0619820A2 (en) | 2005-12-13 | 2006-12-13 | method of extracorporeal removal of a pathogen, an inflammatory cell or an inflammatory blood protein |
JP2008545539A JP5715325B2 (en) | 2005-12-13 | 2006-12-13 | In vitro removal of pathogenic microorganisms, inflammatory cells or inflammatory proteins from blood |
KR1020147002838A KR20140021725A (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
CA2630823A CA2630823C (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US12/086,126 US9173989B2 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
KR1020087016993A KR101397386B1 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
DK06835845.6T DK1960016T3 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal by a pathogenic MI-KROBE, an inflammatory cell or inflammatory protein from the blood. |
MX2014008924A MX344592B (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood. |
ES06835845.6T ES2608399T3 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from the blood |
US14/873,133 US9764077B2 (en) | 2005-12-13 | 2015-10-01 | Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US15/678,580 US10188783B2 (en) | 2005-12-13 | 2017-08-16 | Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US16/247,372 US10688239B2 (en) | 2005-12-13 | 2019-01-14 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US16/893,249 US11065378B2 (en) | 2005-12-13 | 2020-06-04 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0502750-3 | 2005-12-13 | ||
SE0502750 | 2005-12-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/086,126 A-371-Of-International US9173989B2 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US14/873,133 Continuation US9764077B2 (en) | 2005-12-13 | 2015-10-01 | Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007069983A1 true WO2007069983A1 (en) | 2007-06-21 |
Family
ID=38163194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2006/001421 WO2007069983A1 (en) | 2005-12-13 | 2006-12-13 | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
Country Status (14)
Country | Link |
---|---|
US (5) | US9173989B2 (en) |
EP (1) | EP1960016B1 (en) |
JP (3) | JP5715325B2 (en) |
KR (2) | KR20140021725A (en) |
CN (2) | CN103203048A (en) |
AU (1) | AU2006325531B2 (en) |
BR (1) | BRPI0619820A2 (en) |
CA (1) | CA2630823C (en) |
DK (1) | DK1960016T3 (en) |
ES (1) | ES2608399T3 (en) |
HU (1) | HUE029958T2 (en) |
MX (2) | MX344592B (en) |
RU (1) | RU2432187C2 (en) |
WO (1) | WO2007069983A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008157570A3 (en) * | 2007-06-18 | 2009-07-16 | Exthera Ab | Device and method for restoration of the condition of blood |
WO2011068897A1 (en) * | 2009-12-01 | 2011-06-09 | Exthera Medical, Llc | Method for removing cytokines from blood with surface immobilized polysaccharides |
WO2011133099A1 (en) * | 2010-04-21 | 2011-10-27 | Exthera Medical Llc | Method for removal of mrsa from blood |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
RU2500434C1 (en) * | 2012-11-28 | 2013-12-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" | Method of treating sepsis accompanying abdominal and retroperitoneal diseases |
EP2682140A1 (en) * | 2011-03-04 | 2014-01-08 | DIC Corporation | Sugar-immobilized polymer substrate for removing viruses, and method for removing viruses |
US9173989B2 (en) | 2005-12-13 | 2015-11-03 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
RU2572019C1 (en) * | 2014-11-12 | 2015-12-27 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method of treating sepsis in treating abdominal organs complicated by hepatic failure |
AU2014277852B2 (en) * | 2009-12-01 | 2016-08-25 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
US9669150B2 (en) | 2007-06-18 | 2017-06-06 | Exthera Medical Corporation | Device and method for restoration of the condition of blood |
EP3362794A4 (en) * | 2013-11-08 | 2019-07-24 | ExThera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
US10639413B2 (en) | 2013-06-24 | 2020-05-05 | Exthera Medical Corporation | Blood filtration system containing mannose coated substrate |
US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
US10857283B2 (en) | 2014-09-22 | 2020-12-08 | Exthera Medical Corporation | Wearable hemoperfusion device |
US11266772B2 (en) | 2012-06-13 | 2022-03-08 | Exthera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
EP3981505A1 (en) * | 2020-10-12 | 2022-04-13 | Gambro Lundia AB | Membrane with immobilized anticoagulant and process for producing same |
US11844895B2 (en) | 2014-04-24 | 2023-12-19 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
US12090261B2 (en) | 2019-05-16 | 2024-09-17 | Exthera Medical Corporation | Method for modulating endothelial glycocalyx structure |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5692738B2 (en) * | 2009-07-28 | 2015-04-01 | 国立大学法人 鹿児島大学 | Virus concentration method and magnetic composition |
US20120305482A1 (en) * | 2010-02-09 | 2012-12-06 | Exthera Medical, Llc | Removal of virulence factors through extracorporeal therapy |
EP3229996A4 (en) * | 2014-12-12 | 2018-09-05 | Velo3d Inc. | Feedback control systems for three-dimensional printing |
JP2016146809A (en) * | 2015-02-13 | 2016-08-18 | 国立大学法人広島大学 | Viral isolation device |
TWI580782B (en) * | 2015-08-11 | 2017-05-01 | 財團法人工業技術研究院 | Biochemistry reactive materialand device for eliminating low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate low-density lipoprotein therein |
US20170044516A1 (en) | 2015-08-11 | 2017-02-16 | Industrial Technology Research Institute | Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein |
WO2018101156A1 (en) * | 2016-11-29 | 2018-06-07 | 富士フイルム株式会社 | Blood component selective adsorption filtering medium and blood filter |
JP6231236B1 (en) * | 2017-03-30 | 2017-11-15 | 株式会社日立製作所 | Friction stir welding apparatus, friction stir welding control apparatus, and friction stir welding method |
CN112088023B (en) | 2018-01-05 | 2024-05-14 | 帕斯艾克斯公司 | Device for capturing and removing disease substances in a fluid |
JP2022550403A (en) | 2019-09-30 | 2022-12-01 | ヘモチューン アーゲー | Assembly for extracorporeal treatment of body fluids |
CN114042441B (en) * | 2021-12-09 | 2024-05-03 | 云南师范大学 | Method for modifying and immobilizing heparin on surface of hemoperfusion resin microsphere and adsorbent prepared by method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
EP1044696A2 (en) * | 1999-04-12 | 2000-10-18 | B. Braun Melsungen Ag | Removal of enveloped viruses from blood, plasma or serum |
US6197568B1 (en) * | 1997-07-29 | 2001-03-06 | The Regents Of The University Of Michigan | Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3782382A (en) | 1972-02-03 | 1974-01-01 | K N Enterprises Inc | Means for blood administration and the like |
US4103685A (en) | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
JPS54127493U (en) | 1978-02-25 | 1979-09-05 | ||
JPS6040926B2 (en) | 1979-07-24 | 1985-09-13 | 三菱重工業株式会社 | Automatic support device for mandrel bar |
US4430496A (en) | 1980-01-17 | 1984-02-07 | Varian Associates, Inc. | Strong anion exchange composition and methods |
US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
JPS5853757A (en) | 1981-09-25 | 1983-03-30 | Denki Kagaku Kogyo Kk | Adsorbent for immuno-affinity chromatography and manufacture of same |
SE8200751L (en) | 1982-02-09 | 1983-08-10 | Olle Larm | PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS |
JPS58146354A (en) | 1982-02-26 | 1983-08-31 | 日機装株式会社 | Production of body liquid washer |
US4820302A (en) | 1982-04-22 | 1989-04-11 | Sterling Drug Inc. | Bio compatible and blood compatible materials and methods |
CA1221307A (en) | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
DE3609021A1 (en) | 1985-03-25 | 1986-09-25 | Bio-Rad Laboratories, Inc., Richmond, Calif. | CHROMATOGRAPHIC SEPARATION MEDIUM FOR FAST ANALYSIS OF SMALL SAMPLES |
DE3519011A1 (en) | 1985-05-25 | 1986-11-27 | Behringwerke Ag, 3550 Marburg | METHOD FOR PRODUCING A MATERIAL FOR AFFINITY CHROMATOGRAPHY |
CA1327963C (en) | 1987-09-08 | 1994-03-22 | Ryuichi Yokohari | Autoantibody adsorbent and apparatus for removing autoantibodies using the same |
DE3853219T2 (en) | 1987-11-20 | 1995-06-29 | Kanegafuchi Chemical Ind | Method of removing serum amyloid protein. |
US4955870A (en) | 1988-08-23 | 1990-09-11 | Ridderheim Kristen A | Hypodermic syringe with retractable needle |
WO1991004086A1 (en) | 1989-09-18 | 1991-04-04 | Cuno, Incorporated | Filter media and use for pyrogen removal |
JPH0489500A (en) | 1990-07-31 | 1992-03-23 | Kirin Brewery Co Ltd | Method for purifying substance by affinity chromatography and apparatus for purification |
SE469256B (en) | 1991-02-18 | 1993-06-14 | Medscand Ab | RENGOERINGSPRODUKT |
AU648655B2 (en) | 1991-03-26 | 1994-04-28 | Otsuka Pharmaceutical Factory, Inc. | Adsorbed cellular fibronectin and process for separating and purifying fibronectins |
US5211850A (en) | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
DE4217917A1 (en) | 1992-05-30 | 1993-12-02 | Job Prof Dr Med Harenberg | Heparin-polymer conjugate used to inhibit coagulation in analytical tests - comprises heparin fragments bonded to amino-phenyl substd. polymer |
JPH0640926A (en) * | 1992-07-24 | 1994-02-15 | Chemo Sero Therapeut Res Inst | Method for removing hepatitis c virus |
DE4331358A1 (en) | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Process for the quantitative selective removal or preparation of tumor necrosis factor (TNF) and / or lipopolysaccharides (LPS) from aqueous liquids |
US5344455A (en) | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
US5437861A (en) * | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
JP2643823B2 (en) | 1993-03-25 | 1997-08-20 | 有限会社 エンゼル総合研究所 | Adsorption material and method for producing the same |
NO931809L (en) | 1993-05-19 | 1994-11-21 | Norsk Hydro As | hemophilia |
US5753227A (en) | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
CN1130386A (en) * | 1993-08-19 | 1996-09-04 | 美国3M公司 | Heparin functional affinity supports |
JPH07178161A (en) | 1993-12-24 | 1995-07-18 | Terumo Corp | Medical instrument |
EP0810027B1 (en) | 1995-02-16 | 2002-06-05 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for tumor necrosis factor alpha, method of removal by adsorption, and adsorption device using said adsorbent |
SE9501056D0 (en) | 1995-03-23 | 1995-03-23 | Probi Ab | Epithelial adherent lactobacilli |
US6312907B1 (en) | 1995-04-24 | 2001-11-06 | The Texas A & M University System | DbpA compositions and methods of use |
AU6267796A (en) | 1995-06-07 | 1996-12-30 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
CA2229986C (en) | 1995-06-20 | 2014-10-21 | Johannes Schumacher | Process and device for determining the activity of enzymes in liquids, or the concentration and/or activity of inhibitors in liquids |
EP0796865B1 (en) | 1996-03-18 | 2003-06-04 | Kaneka Corporation | Adsorbent and method for removing chemokines of the CC subtype from body fluids |
RU2089283C1 (en) | 1996-03-23 | 1997-09-10 | Научно-исследовательская фирма "Ультрасан" | Bio- and heme-compatible sorbents based on super-cross-linked styrene polymers with modified surface, method of preparation thereof (versions), and method of preparing sorbent matrix |
SE507028C2 (en) | 1996-08-06 | 1998-03-16 | Medicarb Ab | New medical use |
AU5811498A (en) | 1996-12-31 | 1998-07-31 | Robert L. Stephon | Microsphere-enhanced immunoassay for the detection of veterinary diseases |
US20010018179A1 (en) | 1998-01-06 | 2001-08-30 | Derek J. Hei | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
CA2284619A1 (en) | 1997-03-25 | 1998-10-01 | Kaneka Corporation | Absorbent for eliminating hepatitis c virus, absorber, and absorption method |
US6465170B2 (en) | 1997-06-13 | 2002-10-15 | Baxter Aktiengesellschaft | Method for depleting viral and molecular pathogens in a biological material |
US20020197249A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products |
US20020159995A1 (en) | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
US20020197250A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
US6053894A (en) | 1997-08-04 | 2000-04-25 | Shadd, Jr.; Daniel L. | Hypodermic syringe |
US7611831B2 (en) | 1998-01-06 | 2009-11-03 | Cerus Corporation | Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix |
US6136424A (en) | 1998-02-06 | 2000-10-24 | Renal Tech International, Llc | Method of and material for purification of physiological liquids of organism, and method of producing the material |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
JP2000086688A (en) | 1998-09-04 | 2000-03-28 | Ngk Insulators Ltd | Parbovirus-absorbing sugar-chain ligand, and prabovirus- removing device by using the same |
NO984143L (en) | 1998-09-09 | 2000-03-10 | Norsk Hydro As | New process for producing surface modifying substances |
EP1123501A4 (en) | 1998-10-19 | 2005-04-13 | Cbd Technologies Ltd | Methods of concentrating microorganisms using affinity separation |
EP1057529A4 (en) | 1998-12-22 | 2004-08-25 | Toray Industries | Materials for removing bacterial components |
US6659289B1 (en) | 1998-12-24 | 2003-12-09 | Toray Industries, Inc. | Hemocathartic column for purifying blood |
JP2000217575A (en) | 1999-02-01 | 2000-08-08 | Masashi Funayama | Adsorbent of physiologically active substance, human blood cell differentiation cell and human cell |
US6531159B1 (en) | 1999-04-28 | 2003-03-11 | Toray Industries, Inc. | Materials eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same |
EP1219639A4 (en) | 1999-09-08 | 2009-03-25 | Toray Industries | Materials for extracorporeal circulation, adsorbents for diabetic complication factors, containers for eliminating diabetic complication factors and method of eliminating diabetic complication factors |
SE515295C2 (en) * | 1999-11-23 | 2001-07-09 | Medicarb Ab | Process for the preparation of conjugates of a biologically active polysaccharide and a solid substrate, and such conjugates |
JP2001178817A (en) | 1999-12-24 | 2001-07-03 | Terumo Corp | Device for artificial kidney, quality evaluating device using the same and fluid circuit |
US7067060B2 (en) | 2000-01-11 | 2006-06-27 | Nephros, Inc. | Ionic enhanced dialysis/diafiltration system |
JP2001190273A (en) | 2000-01-14 | 2001-07-17 | Jsr Corp | Particle for concentrating virus, method for concentrating and detecting the virus by using the particle |
GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
EP1264181B1 (en) | 2000-03-06 | 2007-06-06 | Dade Behring Marburg GmbH | Carriers coated with polysaccharides, their preparation and use |
AU783457B2 (en) | 2000-04-05 | 2005-10-27 | Toray Industries, Inc. | Adsorbents for high mobility group proteins and column for purifying body fluid |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
DE10045434B4 (en) | 2000-09-14 | 2005-07-14 | Fresenius Hemocare Gmbh | Adsorbent with differently modified surface areas, process for its preparation and use thereof |
JP4283430B2 (en) | 2000-09-26 | 2009-06-24 | 株式会社カネカ | Enterotoxin adsorbent, adsorption removal method and adsorber |
US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
US8178304B2 (en) | 2000-10-06 | 2012-05-15 | Smith Terry J | Diagnostic methods relating to Graves' disease and other autoimmune disorders |
US6509104B2 (en) * | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
EP1884274A1 (en) | 2000-12-29 | 2008-02-06 | Upfront Chromatography A/S | Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids |
EP1356832B1 (en) | 2001-01-30 | 2012-07-11 | Kaneka Corporation | Body fluid processor enabling direct hemoperfusion |
DE10117043A1 (en) | 2001-04-05 | 2002-11-07 | Gerhard Puetz | Process for the elimination of potentially toxic and / or harmful substances |
US20020197252A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
US6773412B2 (en) | 2001-04-13 | 2004-08-10 | Chf Solutions, Inc. | User interface for blood treatment device |
KR20040050912A (en) | 2001-10-10 | 2004-06-17 | 가부시키가이샤 노리타케 캄파니 리미티드 | Photocatalytic material selectively inactivating biologically harmful substance and utilization thereof |
JP2003128502A (en) | 2001-10-18 | 2003-05-08 | Noritake Co Ltd | Treating material for harmful substance and method for producing the same |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
US20030148017A1 (en) | 2001-12-07 | 2003-08-07 | Olli Tuominen | Copolymer coating for a hydrophobic membrane |
AU2003213758A1 (en) | 2002-03-14 | 2003-09-29 | Fenwal, Inc. | Compound removal device |
WO2003090781A1 (en) | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
AU2003242509A1 (en) | 2002-07-11 | 2004-02-02 | Upfront Chromatography A/S | An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis |
WO2004009798A2 (en) | 2002-07-24 | 2004-01-29 | Ciphergen Biosystems, Inc. | Protein interaction difference mapping |
US20040182783A1 (en) | 2003-03-17 | 2004-09-23 | Walker Kimberly A. | Filter and concentrator device for treatment of blood |
US7207964B2 (en) | 2003-03-17 | 2007-04-24 | Hemavation, Llc | Apparatus and method for down-regulating immune system mediators in blood |
DK2103694T3 (en) | 2003-08-15 | 2011-09-12 | Univ South Florida | Materials and Methods for Capturing Pathogens and Removing aurintricarboxylic Acid from a Sample |
US7399400B2 (en) | 2003-09-30 | 2008-07-15 | Nano-Proprietary, Inc. | Nanobiosensor and carbon nanotube thin film transistors |
WO2005051313A2 (en) | 2003-11-19 | 2005-06-09 | Chiron Corporation | Methods and reagents for treating, preventing and diagnosing bunyavirus infection |
KR101236046B1 (en) | 2004-07-23 | 2013-02-21 | 카네카 코포레이션 | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
EP1792635B1 (en) | 2004-08-30 | 2014-05-21 | Kaneka Corporation | Granulocyte adsorbent |
US8445293B2 (en) | 2005-02-09 | 2013-05-21 | Rapid Pathogen Screening, Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
GB0509433D0 (en) | 2005-05-09 | 2005-06-15 | Uni For Milj Og Biovitenskap | Method |
WO2007002480A2 (en) | 2005-06-24 | 2007-01-04 | Board Of Regents, The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
US20100239673A1 (en) | 2005-08-01 | 2010-09-23 | Linhardt Robert J | Blood compatible nanomaterials and methods of making and using the same |
AU2006316039B2 (en) | 2005-11-21 | 2011-08-18 | Ge Healthcare Bio-Sciences Ab | A method of chromatography using semi-synthetic heparin ligands |
CA2630823C (en) | 2005-12-13 | 2015-02-10 | Exthera Ab | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
CN103235147B (en) | 2005-12-21 | 2015-08-12 | 梅索斯卡莱科技公司 | The liquid distributor of analytical equipment |
JP5254043B2 (en) | 2006-02-22 | 2013-08-07 | ヘンリー フォード ヘルス システム | Topical citrate anticoagulant delivery system and method to extracorporeal blood circuit |
WO2007146162A2 (en) | 2006-06-08 | 2007-12-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Devices, systems and methods for reducing the concentration of a chemical entity in fluids |
JP4934133B2 (en) | 2006-06-16 | 2012-05-16 | テルモ株式会社 | Blood processing filter and blood processing circuit |
FR2902670B1 (en) | 2006-06-22 | 2009-04-24 | Gambro Lundia Ab | USE OF A SUSPENSION FOR TREATING MEDICAL MEDIA, MEDICAL MEDIA, EXCHANGER, AND ADSORPTION DEVICE COMPRISING THE MEDIUM |
WO2008147382A1 (en) | 2006-09-27 | 2008-12-04 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
WO2008051762A2 (en) | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
GB0702183D0 (en) | 2007-02-05 | 2007-03-14 | Iti Scotland Ltd | Pathogen binding |
WO2008128251A1 (en) | 2007-04-17 | 2008-10-23 | The Children's Hospital Of Philadelphia | Humanized viral vectors and methods of use thereof |
US20100145317A1 (en) | 2007-04-19 | 2010-06-10 | Morris Laster | Device system and method for monitoring and controlling blood analyte levels |
WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
JP2010530288A (en) | 2007-06-18 | 2010-09-09 | エクステラ・メディカル・エルエルシー | Device and method for recovering blood condition |
JP4226050B1 (en) | 2007-09-12 | 2009-02-18 | 株式会社Reiメディカル | Absorption column for body fluid purification treatment |
JP2011502703A (en) | 2007-11-16 | 2011-01-27 | スミス アンド ネフュー インコーポレーテッド | Annular ring graft |
WO2009086343A2 (en) | 2007-12-31 | 2009-07-09 | 3M Innovative Properties Company | Microorganism-capturing compositions and methods |
EP2087916A1 (en) | 2008-02-11 | 2009-08-12 | ICinnovation BV | Electrosorption device for the purification of blood and other fluids |
CN101632686A (en) | 2008-04-04 | 2010-01-27 | 马斯特里赫特大学 | Use of glycosaminoglycan for restoring glycocalyx |
US9242036B2 (en) | 2008-06-23 | 2016-01-26 | Temasek Polytechnic | Sorbent for a dialysis device |
WO2010029317A2 (en) | 2008-09-10 | 2010-03-18 | Ibd Column Therapies International Ab | Treating inflammatory conditions |
US8310415B2 (en) | 2008-09-30 | 2012-11-13 | Animas Corporation | Medical devices using bistable displays |
US8454547B2 (en) | 2009-02-25 | 2013-06-04 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8801922B2 (en) | 2009-06-24 | 2014-08-12 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Dialysis system |
DE112010003137T5 (en) | 2009-07-31 | 2012-06-06 | Board Of Regents, The University Of Texas System | PROPHYLAXIS AGAINST CANCER TREATMENT |
CA2967094C (en) | 2009-12-01 | 2022-08-16 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
US20120305482A1 (en) | 2010-02-09 | 2012-12-06 | Exthera Medical, Llc | Removal of virulence factors through extracorporeal therapy |
WO2011133287A1 (en) | 2010-04-19 | 2011-10-27 | The Trustees Of Columbia University In The City Of New York | Portable blood filtration devices, systems, and methods |
JP2014500735A (en) | 2010-10-15 | 2014-01-16 | サイトフェリックス インコーポレイテッド | Cytopheresis cartridge and its use |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
US8563713B2 (en) | 2011-03-02 | 2013-10-22 | Guangzhou Kingmed Center for Clinical Laboratory | Antibodies specific to carbamazepine |
US20130131423A1 (en) | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
EP2717941B1 (en) | 2011-06-13 | 2020-04-01 | TLA Targeted Immunotherapies AB | Treating cancer |
JP2014523914A (en) | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Engineered microbial targeting molecules and uses thereof |
EP2556849A1 (en) | 2011-08-08 | 2013-02-13 | Gambro Lundia AB | Separation material |
ES2647577T3 (en) | 2012-06-13 | 2017-12-22 | Exthera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
WO2014085713A1 (en) | 2012-11-30 | 2014-06-05 | The Methodist Hospital Research Institute | Methods and compositions for detecting tuberculosis |
GB201302774D0 (en) | 2013-02-18 | 2013-04-03 | Sphere Medical Ltd | Analyte extraction apparatus and method |
BR112015032134B1 (en) | 2013-06-24 | 2022-05-10 | Exthera Medical Corporation | Method of end-linking a non-reducing mannose to a substrate and bead having an end-linked mannose |
WO2015048301A1 (en) | 2013-09-26 | 2015-04-02 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
ES2799398T3 (en) | 2013-11-08 | 2020-12-17 | Exthera Medical Corp | Methods for diagnosing infectious diseases using adsorption media |
JP6040926B2 (en) | 2013-12-16 | 2016-12-07 | 株式会社オートネットワーク技術研究所 | Board built-in connector |
WO2015164198A1 (en) | 2014-04-24 | 2015-10-29 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
JP7100454B2 (en) | 2014-09-22 | 2022-07-13 | エクスセラ メディカル コーポレイション | Wearable blood perfusion device |
EP3422943A4 (en) | 2016-03-02 | 2019-10-16 | ExThera Medical Corporation | Method for treating drug intoxication |
US10711831B2 (en) | 2017-03-02 | 2020-07-14 | Raytheon Company | Flexural pivot |
BR112020014189B1 (en) | 2018-01-10 | 2022-07-12 | XWPharma Ltd. | COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF COMPOUND |
US20200023001A1 (en) | 2018-07-20 | 2020-01-23 | Northeastern University | GlycoFix (Structurally And Functionally Repaired Endothelial Glycocalyx) |
-
2006
- 2006-12-13 CA CA2630823A patent/CA2630823C/en active Active
- 2006-12-13 BR BRPI0619820-1A patent/BRPI0619820A2/en not_active Application Discontinuation
- 2006-12-13 US US12/086,126 patent/US9173989B2/en active Active
- 2006-12-13 JP JP2008545539A patent/JP5715325B2/en active Active
- 2006-12-13 RU RU2008128416/14A patent/RU2432187C2/en active
- 2006-12-13 ES ES06835845.6T patent/ES2608399T3/en active Active
- 2006-12-13 KR KR1020147002838A patent/KR20140021725A/en not_active Application Discontinuation
- 2006-12-13 AU AU2006325531A patent/AU2006325531B2/en active Active
- 2006-12-13 WO PCT/SE2006/001421 patent/WO2007069983A1/en active Application Filing
- 2006-12-13 EP EP06835845.6A patent/EP1960016B1/en active Active
- 2006-12-13 MX MX2014008924A patent/MX344592B/en unknown
- 2006-12-13 KR KR1020087016993A patent/KR101397386B1/en active IP Right Grant
- 2006-12-13 CN CN2013100911452A patent/CN103203048A/en active Pending
- 2006-12-13 MX MX2008007716A patent/MX2008007716A/en active IP Right Grant
- 2006-12-13 HU HUE06835845A patent/HUE029958T2/en unknown
- 2006-12-13 DK DK06835845.6T patent/DK1960016T3/en active
- 2006-12-13 CN CNA2006800527579A patent/CN101370536A/en active Pending
-
2013
- 2013-07-19 JP JP2013150237A patent/JP5868356B2/en active Active
-
2015
- 2015-08-28 JP JP2015168707A patent/JP2016027047A/en active Pending
- 2015-10-01 US US14/873,133 patent/US9764077B2/en active Active
-
2017
- 2017-08-16 US US15/678,580 patent/US10188783B2/en active Active
-
2019
- 2019-01-14 US US16/247,372 patent/US10688239B2/en active Active
-
2020
- 2020-06-04 US US16/893,249 patent/US11065378B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
US6197568B1 (en) * | 1997-07-29 | 2001-03-06 | The Regents Of The University Of Michigan | Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms |
EP1044696A2 (en) * | 1999-04-12 | 2000-10-18 | B. Braun Melsungen Ag | Removal of enveloped viruses from blood, plasma or serum |
Non-Patent Citations (3)
Title |
---|
FUJITA M. ET AL.: "Adsorption of Inflammatory Cytokines Using a Heparin-Coated Extracorporeal Circuit", ARTIFICIAL ORGANS, vol. 26, no. 12, 2002, pages 1020 - 1025, XP003009942 * |
HIRMO S. ET AL.: "Sialylgylcoconjugate- and proteoglycan-binding microbial lectins", INSTITUTE OF MEDICAL MICROBIOLOGY, UNIVERSITY OF LUND, XP003009943 * |
WIER D.M.: "Carbohydrates as recognition molecules in infection and immunity", FEMS MICROBIOLOGY IMMUNOLOGY, vol. 47, 1989, pages 331 - 340, XP003009944 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10188783B2 (en) | 2005-12-13 | 2019-01-29 | Exthera Medical Corporation | Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US9764077B2 (en) | 2005-12-13 | 2017-09-19 | Exthera Medical Corporation | Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US10688239B2 (en) | 2005-12-13 | 2020-06-23 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US11065378B2 (en) | 2005-12-13 | 2021-07-20 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
US9173989B2 (en) | 2005-12-13 | 2015-11-03 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
WO2008157570A3 (en) * | 2007-06-18 | 2009-07-16 | Exthera Ab | Device and method for restoration of the condition of blood |
US9669150B2 (en) | 2007-06-18 | 2017-06-06 | Exthera Medical Corporation | Device and method for restoration of the condition of blood |
US8663148B2 (en) | 2007-06-18 | 2014-03-04 | Exthera Medical Corporation | Device and method for restoration of the condition of blood |
US11123466B2 (en) | 2009-12-01 | 2021-09-21 | Exthera Medical Corporation | Methods for removing cytokines from blood with surface immobilized polysaccharides |
AU2010326028B2 (en) * | 2009-12-01 | 2014-10-02 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
US8758286B2 (en) | 2009-12-01 | 2014-06-24 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
US9408962B2 (en) | 2009-12-01 | 2016-08-09 | Exthera Medical Corporation | Methods for removing cytokines from blood with surface immobilized polysaccharides |
AU2014277852B2 (en) * | 2009-12-01 | 2016-08-25 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
US10086126B2 (en) | 2009-12-01 | 2018-10-02 | Exthera Medical Corporation | Methods for removing cytokines from blood with surface immobilized polysaccharides |
WO2011068897A1 (en) * | 2009-12-01 | 2011-06-09 | Exthera Medical, Llc | Method for removing cytokines from blood with surface immobilized polysaccharides |
WO2011133099A1 (en) * | 2010-04-21 | 2011-10-27 | Exthera Medical Llc | Method for removal of mrsa from blood |
US10537280B2 (en) | 2011-02-15 | 2020-01-21 | Exthera Medical Corporation | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
EP2682140A4 (en) * | 2011-03-04 | 2014-07-30 | Dainippon Ink & Chemicals | Sugar-immobilized polymer substrate for removing viruses, and method for removing viruses |
EP2682140A1 (en) * | 2011-03-04 | 2014-01-08 | DIC Corporation | Sugar-immobilized polymer substrate for removing viruses, and method for removing viruses |
US11266772B2 (en) | 2012-06-13 | 2022-03-08 | Exthera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
RU2500434C1 (en) * | 2012-11-28 | 2013-12-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" | Method of treating sepsis accompanying abdominal and retroperitoneal diseases |
US10639413B2 (en) | 2013-06-24 | 2020-05-05 | Exthera Medical Corporation | Blood filtration system containing mannose coated substrate |
US11306346B2 (en) | 2013-11-08 | 2022-04-19 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
US10487350B2 (en) | 2013-11-08 | 2019-11-26 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
EP3362794A4 (en) * | 2013-11-08 | 2019-07-24 | ExThera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
US10457974B2 (en) | 2013-11-08 | 2019-10-29 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
US11844895B2 (en) | 2014-04-24 | 2023-12-19 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
US10857283B2 (en) | 2014-09-22 | 2020-12-08 | Exthera Medical Corporation | Wearable hemoperfusion device |
RU2572019C1 (en) * | 2014-11-12 | 2015-12-27 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method of treating sepsis in treating abdominal organs complicated by hepatic failure |
US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
US12090261B2 (en) | 2019-05-16 | 2024-09-17 | Exthera Medical Corporation | Method for modulating endothelial glycocalyx structure |
EP3981505A1 (en) * | 2020-10-12 | 2022-04-13 | Gambro Lundia AB | Membrane with immobilized anticoagulant and process for producing same |
WO2022078785A1 (en) | 2020-10-12 | 2022-04-21 | Gambro Lundia Ab | Membrane with immobilized anticoagulant and process for producing same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11065378B2 (en) | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood | |
JP6031069B2 (en) | Apparatus and method for restoring blood pathology | |
US9669150B2 (en) | Device and method for restoration of the condition of blood | |
JP5925693B2 (en) | Method for removing cytokines from blood using surface-immobilized polysaccharides | |
JP5774607B2 (en) | Removal of toxic factors by in vitro treatment | |
JPH0431735B2 (en) | ||
JPH0779693B2 (en) | Blood coagulation factor IX adsorbent and method for purifying blood coagulation factor IX using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2054/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2630823 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006325531 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 568754 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/007716 Country of ref document: MX Ref document number: 2008545539 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006325531 Country of ref document: AU Date of ref document: 20061213 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2006835845 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006835845 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087016993 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008128416 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052757.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12086126 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0619820 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080613 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147002838 Country of ref document: KR |